Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

CNMD US Equity

CONMED CorpHealth Care · Electromedical & Electrotherapeutic Apparatus · CIK 816956 · FY ends Dec 31
$49.26
+0.01 (+0.02%)
USD · as of 2026-08-18 · marketstack
2 registered studies · 2 active

Studies where CNMD is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.

1 interventional · 1 observational

Held by 10 tracked-famous managers (TWO SIGMA INVESTMENTS, LP, AQR CAPITAL MANAGEMENT LLC, MARSHALL WACE, LLP, CITADEL ADVISORS LLC, JANE STREET GROUP, LLC, +5 more) · FINRA short interest 3.5 days to cover (settled 2026-07-31) · government filings 180d: 0 congress / 1 executive

StudyPhaseStatusInterventionsConditionsEnrollmentPrimary completionReadout inUpdated
BioBrace® Augmentation in Anterior Cruciate Ligament Reconstruction ProceduresNCT06948591observationalImprovement in FunctionRecruitingDevice: Anterior cruciate ligament reconstruction with BioBrace® augmentation · Procedure: Arthroscopic anterior cruciate ligament reconstructionACL Tears500Jun 2030≤ 1,411 d2026-04-14
BioBrace® Implant for Arthroscopic Repair of Full Thickness Rotator Cuff TearsNCT059973816 Month Retear RateRandomized · Single-masked · TreatmentNot applicableRecruitingDevice: Arthroscopic rotator cuff repair with BioBrace® Implant augmentation. · Procedure: Arthroscopic rotator cuff repairRotator Cuff Tears268Dec 2026≤ 134 d2026-04-23

Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.

Source: ClinicalTrials.gov, retrieved 2026-08-19